Evidence level: B
中医说”同病异治”、说要”辨体论治”,但”按体质开处方”比”统一推荐”到底多值多少钱,不是一个信仰问题,而是一个可以随机对照试验测量的增量问题——而且现代营养学的头对头试验给出的答案,比想象中更耐人寻味。
正文
“你是痰湿体质,要少吃甜腻;他是阴虚体质,要忌辛辣燥热。”中医体质学说的核心承诺,就是每个人的处方应该不一样——同样的目标,路线不同。这个承诺听起来天经地义,但它隐含着一个可以被科学检验的假设:“个性化”的处方,比”标准化”的处方,能带来额外的好处。 这个”额外的好处”,流行病学上叫”增量价值”,检验它的金标准叫头对头随机对照试验(head-to-head RCT):把一群人随机分成两组,一组按体质分型开处方,一组按统一指南开处方,看谁的体质评分和代谢指标改善更多。
现代营养学已经替中医先做了一轮这类试验,结果第一条是:个性化确实赢,但赢得很”挑食”。 欧洲最大的个性化营养试验 Food4Me(7 国、1269 人完成随访)把人随机分到四组:常规建议组、按饮食基线个性化组、加表型(人体测量+血液标志物)组、再加基因型(5 个饮食相关基因位点)组。6 个月后,任何形式的个性化建议都比常规建议更有效地改变了饮食行为——红肉摄入少 5.48g/天、盐少 0.65g/天、饱和脂肪少 1.14% 能量占比、健康饮食指数高 1.27 分。但最反直觉的发现是:加上表型、加上基因型,并没有比单纯按饮食基线个性化更有效(PMID 27524815)。也就是说,”个性化”的溢价来自”针对你这个人”,而不一定来自”测了你的基因”。
第二条:个性化的赢面是”局部”的,不是”全面”的。 2024 年发表在 Nature Medicine 的 ZOE 试验(347 人,18 周)把”个性化饮食程序”(结合餐后血糖/甘油三酯反应、肠道菌群、健康史的算法评分)与”美国膳食指南标准建议”对比,结果是:甘油三酯显著下降(组间差 −0.13 mmol/L,P=0.016),体重、腰围、HbA1c、饮食质量也改善,但LDL 胆固醇这个主要终点没赢(PMID 38714898)。同样是”个性化 vs 一刀切”,在不同指标上输赢不同——这说明个性化溢价是按终点结算的,不是打包到账。
第三条来自中国自己的证据,也是离体质学说最近的一条。 Diet2Me 试验把 400 名中国超重/肥胖成人(BMI≥24)随机分到”个性化营养组”(基于人体测量、血液表型、基因型、膳食和运动的决策树处方,每两周更新)和”常规指南组”(中国居民膳食指南)。12 周后,个性化组的 BMI、体脂率、腰围、血脂、尿酸、同型半胱氨酸全面优于对照组,而且优势是通过行为改变实现的——个性化组的膳食指南指数和体力活动水平更高(PMID 35811975)。这是目前中国人群里”个性化 vs 一刀切”最直接的 RCT 证据,说明在中国的饮食文化背景下,个性化处方的增量价值成立。
但第四条证据给狂热泼了盆冷水:把 15 个 RCT 汇总起来看,个性化的整体赢面其实很温和。 2025 年发表的系统综述和 meta 分析(15 项 RCT)发现,个性化营养对收缩压(WMD −1.91 mmHg)和舒张压(−1.49 mmHg)以及饮食摄入有改善,但对血脂和人体测量指标的结果不一致;而且 46.7% 的研究连个性化的定义和框架都不一样,作者呼吁先建立标准化框架再谈疗效(PMID 39420556)。换句话说:“个性化”三个字本身不是疗效保证,它必须说清楚”基于什么个性化”才有可重复的溢价。
中医的辨体处方,本质上就是”基于体质问卷(CCMQ)个性化”。目前最接近的直接证据,是一项按中医辨证(阳虚/阴虚/气虚/血虚)指导膳食的 RCT:3 个月后干预组的气虚、阴虚、血虚证候评分显著改善,而对照组多项证候反而恶化(PMID 31871480)。但场景是戒毒戒断青年男性,样本小、人群特殊,距离”九种体质×处方 vs 标准处方”的头对头设计还差得远。
把五条证据链拼起来,答案就清晰了:“辨体 vs 一刀切”的增量价值,在营养学领域已被部分证实(饮食行为、甘油三酯、血压、BMI 有溢价),但溢价是终点特异的、量级温和的、且高度依赖”个性化的依据”是否可重复。 中医体质学说如果要把”辨体论治”做成现代证据,缺的不是理念,而是一场设计严谨的头对头 RCT:随机分派到”辨体处方”和”标准处方”,用 CCMQ 复评的 Δ体质评分和代谢双终点做主次结局,再用 PRS 分层看遗传背景是否调制增量。
证据与局限
已验证: 个性化营养建议在饮食行为改变上显著优于常规建议(Food4Me,PMID 27524815);个性化饮食程序显著降低甘油三酯但未改善 LDL(ZOE,PMID 38714898);中国超重/肥胖人群中个性化营养全面优于常规指南(Diet2Me,PMID 35811975);中医辨证膳食 RCT 改善证候评分(PMID 31871480)。
部分验证: 15 项 RCT 的 meta 分析显示个性化营养对血压和饮食摄入有益、对血脂和体重结果不一致,且缺乏标准化定义(PMID 39420556)——”个性化溢价”的量级和稳定性存疑。
待验证: “中医九种体质分型处方 vs 标准化处方”的头对头 RCT 本身尚未见报道;Δ体质评分(CCMQ 复评)能否作为增量价值的敏感终点未定;PRS 分层下个性化溢价是否随遗传负荷变化(高 PRS 者是否从辨体处方获益更多)是开放问题。
相关阅读
证据等级: B(中医辨体 vs 一刀切头对头 RCT 尚缺,直接证据来自个性化营养 RCT 与辨证膳食 RCT 的交叉类比)
参考文献: PMID 27524815, PMID 38714898, PMID 35811975, PMID 39420556, PMID 31871480
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Body Constitution vs One-Size-Fits-All: How Much Personalized Value Does Traditional Chinese Medicine Prescribing Offer?
Evidence level: B
Traditional Chinese Medicine (TCM) emphasizes “treating according to differentiation” and the concept of “distinguishing constitution,” yet quantifying the cost-benefit of “constitution-based prescribing” versus “standardized recommendations” is not a matter of faith, but an incremental question measurable via randomized controlled trials (RCTs). The answers provided by head-to-head trials in modern nutrition science are more nuanced than anticipated.
Main Text
“You have a Phlegm-Damp constitution; you should avoid sweet and greasy foods. He has Yin Deficiency; he should avoid spicy and drying heat.” The core promise of TCM constitution theory is that each individual’s prescription should differ—following the same goal but via different pathways. This premise seems self-evident, yet it implies a hypothesis subject to scientific verification: “Personalized” prescriptions yield additional benefits compared to “standardized” ones. In epidemiology, this additional benefit is termed “incremental value,” and the gold standard for testing it is a head-to-head RCT: randomly assigning a cohort to two groups—one receiving prescriptions based on constitution typing, the other following unified guidelines—to compare improvements in constitution scores and metabolic markers.
Modern nutrition science has already conducted such trials, revealing two key findings: Personalization wins, but selectively. The largest personalized nutrition trial in Europe, Food4Me (7 countries, 1,269 participants with follow-up), randomly assigned participants to four groups: standard advice; baseline diet personalization; phenotype addition (anthropometry + blood markers); and genotype addition (5 diet-related gene loci). After 6 months, any form of personalized advice significantly improved dietary behavior compared to standard advice—reducing red meat intake by 5.48g/day, salt by 0.65g/day, saturated fat energy percentage by 1.14%, and increasing the healthy diet index by 1.27 points. However, the most counterintuitive finding was that adding phenotype or genotype did not outperform baseline diet personalization alone (PMID 27524815). In other words, the premium of “personalization” stems from tailoring to the individual, not necessarily from genetic testing.
Secondly, the advantage of personalization is “local,” not “comprehensive.” The 2024 ZOE trial published in Nature Medicine (347 participants, 18 weeks) compared a “personalized diet program” (algorithmic scoring combining postprandial glucose/triglyceride responses, gut microbiota, and health history) against “US Dietary Guidelines standard recommendations.” Results showed significant reductions in triglycerides (between-group difference −0.13 mmol/L, P=0.016), along with improvements in weight, waist circumference, HbA1c, and diet quality. However, LDL cholesterol, the primary endpoint, did not show a significant advantage (PMID 38714898). Thus, in the same “personalization vs. one-size-fits-all” comparison, outcomes vary across metrics—indicating that personalization premiums are settled by endpoint, not bundled.
Thirdly, evidence from China itself aligns closely with constitution theory. The Diet2Me trial randomly assigned 400 Chinese adults with overweight/obesity (BMI≥24) to a “personalized nutrition group” (decision tree prescriptions based on anthropometry, blood phenotypes, genotypes, diet, and exercise, updated biweekly) versus a “standard guideline group” (Chinese居民 Dietary Guidelines). After 12 weeks, the personalized group showed superior BMI, body fat percentage, waist circumference, lipids, uric acid, and homocysteine compared to controls, with advantages driven by behavioral changes—higher dietary guideline adherence and physical activity levels in the personalized group (PMID 35811975). This represents the most direct RCT evidence of “personalization vs. one-size-fits-all” within the Chinese population, confirming incremental value in the context of Chinese dietary culture.
However, a fourth line of evidence cools the enthusiasm: aggregating 15 RCTs reveals a modest overall advantage for personalization. A 2025 systematic review and meta-analysis (15 RCTs) found that personalized nutrition improved systolic blood pressure (WMD −1.91 mmHg), diastolic blood pressure (−1.49 mmHg), and dietary intake, but results were inconsistent for lipids and anthropometric measures; furthermore, 46.7% of studies used different definitions and frameworks for personalization, prompting authors to call for standardized frameworks before claiming efficacy (PMID 39420556). In short: the term “personalization” itself is not a may support of efficacy; reproducible premiums depend on clarifying the basis of personalization.
TCM constitution prescribing is essentially “personalization based on constitution questionnaires (CCMQ).” The closest direct evidence to date is an RCT guiding diet based on TCM syndromic differentiation (Yang Deficiency/Yin Deficiency/Qi Deficiency/Blood Deficiency), where constitution scores in the intervention group significantly improved after 3 months, while several scores worsened in the control group (PMID 31871480). However, the setting involved young men undergoing drug detoxification, with small sample sizes and a specific population, leaving a significant gap from a head-to-head design comparing “nine constitutions × prescription vs. standard prescription.”
Synthesizing these five evidence chains yields a clear conclusion: The incremental value of “differentiation vs. one-size-fits-all” is partially confirmed in nutrition science (premiums observed in dietary behavior, triglycerides, blood pressure, and BMI), but the premium is endpoint-specific, modest in magnitude, and highly dependent on whether the basis of personalization is reproducible. If TCM constitution theory aims to translate “treating according to differentiation” into modern evidence, it lacks not just concepts but a rigorously designed head-to-head RCT: random assignment to “constitution-based prescription” vs. “standard prescription,” using Δ constitution scores (via CCMQ re-evaluation) and metabolic dual endpoints as primary outcomes, and stratifying by Polygenic Risk Score (PRS) to examine whether genetic background modulates the incremental benefit.
Evidence and Limitations
Verified: Personalized nutrition advice significantly outperforms standard advice in dietary behavior change (Food4Me, PMID 27524815); personalized diet programs significantly reduce triglycerides but do not improve LDL (ZOE, PMID 38714898); personalized nutrition comprehensively outperforms standard guidelines in Chinese overweight/obese populations (Diet2Me, PMID 35811975); TCM syndromic diet RCTs improve constitution scores (PMID 31871480).
Partially Verified: Meta-analysis of 15 RCTs indicates personalized nutrition benefits blood pressure and dietary intake but shows inconsistent results for lipids and weight, with a lack of standardized definitions (PMID 39420556)—raising doubts regarding the magnitude and stability of the “personalization premium.”
To Be Verified: A head-to-head RCT specifically comparing “TCM nine-constitution typing prescriptions vs. standardized prescriptions” has not yet been reported; whether Δ constitution scores (via CCMQ re-evaluation) serve as sensitive endpoints for incremental value remains undetermined; whether personalization premiums vary with genetic load under PRS stratification (whether high-PRS individuals benefit more from constitution-based prescriptions) is an open question.
Related Reading
- How Far Can Innate Endowment Be Shifted? Randomized Controlled Trials of Constitution PRS and Lifestyle Interventions
- Personalized vs. Generic Microbiome Interventions: Probiotic Prescriptions Guided by Constitution Typing
- Questionnaire vs. Microbiome Typing: Who Better Predicts Intervention Response?
- Research Pool: Biofrequency Codes
Evidence Level: B (Head-to-head RCTs comparing TCM constitution differentiation vs. one-size-fits-all are still lacking; direct evidence is derived from cross-comparisons of personalized nutrition RCTs and syndromic diet RCTs)
References: PMID 27524815, PMID 38714898, PMID 35811975, PMID 39420556, PMID 31871480
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply